These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36845017)

  • 21. Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers.
    Zeng P; Zhang X; Xiang T; Ling Z; Lin C; Diao H
    Bioengineered; 2022 Feb; 13(2):3221-3239. PubMed ID: 35067176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
    Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
    BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 24. Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.
    Xu J; Ma H; Shan B
    PLoS One; 2022; 17(10):e0273163. PubMed ID: 36194583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
    Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
    Front Immunol; 2021; 12():768115. PubMed ID: 34966389
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer.
    Zhao Q; Liu J
    Front Cell Dev Biol; 2021; 9():754580. PubMed ID: 34966739
    [No Abstract]   [Full Text] [Related]  

  • 27. Comprehensive Multiomic Analysis Identified TUBA1C as a Potential Prognostic Biological Marker of Immune-Related Therapy in Pan-Cancer.
    Zou Y; Wang G; Fan M
    Comput Math Methods Med; 2022; 2022():9493115. PubMed ID: 36466547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker.
    Tu Z; Wang X; Cai H; Sheng Y; Wu L; Huang K; Zhu X
    Aging (Albany NY); 2023 Mar; 15(6):2136-2157. PubMed ID: 36961395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
    Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
    Front Immunol; 2021; 12():646523. PubMed ID: 33679809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.
    Chen R; Wu W; Chen SY; Liu ZZ; Wen ZP; Yu J; Zhang LB; Liu Z; Zhang J; Luo P; Zeng WJ; Cheng Q
    Front Immunol; 2022; 13():831542. PubMed ID: 35979347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy.
    Tu Z; Li K; Ji Q; Huang Y; Lv S; Li J; Wu L; Huang K; Zhu X
    BMC Cancer; 2023 Feb; 23(1):133. PubMed ID: 36759763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PRAME Is a Potential Carcinogenic Biomarker that Correlates with Patient Prognosis and Tumor Immunity Based on Pan-Cancer Analysis.
    Zhao Q; Zhang Z; Wu Y
    Ann Clin Lab Sci; 2022 Mar; 52(2):185-195. PubMed ID: 35414497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
    Mo Z; Li P; Cao Z; Zhang S
    Front Immunol; 2021; 12():564948. PubMed ID: 34290693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and immunological role of SERPINH1 in pan-cancer.
    Zhong H; Wang Z; Wei X; Liu Y; Huang X; Mo X; Tang W
    Front Genet; 2022; 13():900495. PubMed ID: 36105106
    [No Abstract]   [Full Text] [Related]  

  • 39. Identifies KCTD5 as a novel cancer biomarker associated with programmed cell death and chemotherapy drug sensitivity.
    Shi YX; Yan JH; Liu W; Deng J
    BMC Cancer; 2023 May; 23(1):408. PubMed ID: 37149576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.
    Zou W; Li L; Wang Z; Jiang N; Wang F; Hu M; Liu R
    Bioengineered; 2021 Dec; 12(1):9006-9020. PubMed ID: 34654352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.